{"id":117789,"date":"2026-06-23T18:45:29","date_gmt":"2026-06-24T00:45:29","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=117789"},"modified":"2026-06-23T18:45:29","modified_gmt":"2026-06-24T00:45:29","slug":"amycretin-vs-retatrutide-how-two-next-generation-weight-loss-drugs-compare","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/amycretin-vs-retatrutide-how-two-next-generation-weight-loss-drugs-compare\/","title":{"rendered":"Amycretin vs Retatrutide: How Two Next-Generation Weight Loss Drugs Compare"},"content":{"rendered":"

Amycretin and retatrutide are two of the most closely watched experimental obesity drugs in development, and they come from the two companies that already dominate this category<\/a>: Novo Nordisk makes amycretin, and Eli Lilly makes retatrutide. Here’s the short version. Both are still investigational. Neither is FDA approved, and neither is available to buy or prescribe anywhere, including through TrimRx. They work through different mechanisms, come in different forms, and sit at different stages of testing. Retatrutide is further along in trials, while amycretin offers something retatrutide doesn’t: a pill option.<\/p>\n

What Is Amycretin?<\/h3>\n

Amycretin is a drug that activates two appetite-regulating targets with a single molecule: the GLP-1 receptor and the amylin receptor. GLP-1 is the same hormone pathway behind semaglutide (Ozempic and Wegovy). Amylin is a separate hormone that signals fullness and helps slow stomach emptying. Putting both actions into one molecule is the approach Novo Nordisk is betting on.<\/p>\n

In a Phase 1b\/2a study of adults with overweight or obesity, the injectable form produced estimated weight loss of about 9.7% at 20 weeks on a lower dose and roughly 22% at 36 weeks on the 20 mg dose, with no plateau by the end of the study. In November 2025, Novo Nordisk reported Phase 2 results in people with type 2 diabetes, where the injectable form led to up to about 14.5% weight loss and the oral form up to about 10.1% over 36 weeks. Like other drugs in this class, amycretin’s main side effects in trials were gastrointestinal and mostly mild to moderate. Novo Nordisk has leaned on that tolerability, positioning amycretin as a single molecule rather than the two-drug combination (semaglutide plus cagrilintide) in CagriSema, its other amylin-based candidate. Based on these results, both the injection and the pill are moving into Phase 3 testing in 2026.<\/p>\n

What Is Retatrutide?<\/h3>\n

Retatrutide takes a different approach. It’s a once-weekly injection that hits three targets at once: GLP-1, GIP (the second hormone tirzepatide uses), and glucagon, which can raise the rate at which the body burns energy. That third target is why retatrutide is often called a triple agonist, and it’s the first of its kind to reach late-stage trials.<\/p>\n

The major readout came in 2026. In the Phase 3 TRIUMPH-1 trial of 2,339 adults with obesity or overweight, the highest 12 mg dose produced roughly 25% mean weight loss at 80 weeks (and close to 28% in the on-treatment analysis), climbing to about 30% in people who started with more severe obesity. In the highest-dose group, more than a quarter of participants lost at least 35% of their body weight, a level that approaches what some bariatric surgeries achieve. The trial also reported meaningful improvements in knee osteoarthritis pain and obstructive sleep apnea. As with semaglutide and tirzepatide, the most common side effects were gastrointestinal (nausea, diarrhea, constipation, and vomiting), and they were more frequent at higher doses. Dropout from side effects also rose with dose, reaching about 11% on the top dose.<\/p>\n

Amycretin vs Retatrutide at a Glance<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nAmycretin<\/th>\nRetatrutide<\/th>\n<\/tr>\n<\/thead>\n
Developer<\/td>\nNovo Nordisk<\/td>\nEli Lilly<\/td>\n<\/tr>\n
Mechanism<\/td>\nGLP-1 + amylin (one molecule)<\/td>\nGLP-1 + GIP + glucagon (triple agonist)<\/td>\n<\/tr>\n
Form<\/td>\nInjectable and oral<\/td>\nInjectable only<\/td>\n<\/tr>\n
Dosing<\/td>\nWeekly injection or daily pill<\/td>\nWeekly injection<\/td>\n<\/tr>\n
Stage<\/td>\nEntering Phase 3 (2026)<\/td>\nPhase 3 (TRIUMPH program)<\/td>\n<\/tr>\n
Headline weight loss<\/td>\n~22% at 36 weeks (early obesity study)<\/td>\n~25% to 28% at 80 weeks (Phase 3)<\/td>\n<\/tr>\n
FDA status<\/td>\nInvestigational<\/td>\nInvestigational<\/td>\n<\/tr>\n
Available now?<\/td>\nNo<\/td>\nNo<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The Key Differences That Matter<\/h3>\n

Mechanism and targets<\/h4>\n

Both drugs build on GLP-1, but they add different partners. Amycretin pairs GLP-1 with amylin, a combination aimed at strong appetite control with a tolerability profile its makers describe as competitive. Retatrutide adds GIP and glucagon, and that glucagon component is thought to nudge the body to burn more energy, not just eat less. Neither route is clearly better on paper. They’re different paths toward the same goal.<\/p>\n

Pill versus injection<\/h4>\n

This is the clearest practical difference. Retatrutide exists only as a weekly injection. Amycretin is being developed as both a weekly injection and a daily pill. For people who dislike needles, an effective oral option would matter, and oral amycretin’s early weight loss numbers run ahead of what current oral GLP-1 pills have shown. That said, the pill’s results so far trail the injectable version of the same drug.<\/p>\n

How the weight loss results compare<\/h4>\n

It’s tempting to line up the percentages, but the comparison isn’t apples to apples. Retatrutide’s headline figures come from a large, 80-week Phase 3 obesity trial. Amycretin’s strongest obesity numbers come from a smaller, earlier-stage study, and its larger Phase 2 was in people with type 2 diabetes, who typically lose less weight than people without diabetes. For now, retatrutide has the deeper, later-stage evidence. Amycretin’s data looks promising but is earlier, and its Phase 3 results are still years away.<\/p>\n

Where each drug stands in development<\/h4>\n

Retatrutide is ahead. Eli Lilly has said it expects to seek FDA approval around late 2026, possibly into early 2027, which points to a potential launch no sooner than 2027 or 2028 if everything goes well. Amycretin is just beginning Phase 3 in 2026, putting any possible approval further out, likely 2028 at the earliest. In a field that moves this fast, timelines shift often, so treat these as estimates rather than promises.<\/p>\n

Why You Can’t Get Either Drug Yet<\/h3>\n

Because both drugs are investigational, you can’t get them by prescription, and you can’t legally obtain them as compounded versions either. That last point trips people up. Compounding pharmacies can sometimes prepare versions of approved medications under specific conditions, but retatrutide and amycretin aren’t approved, so there’s no legitimate compounded supply of either one.<\/p>\n

You may also see “research-grade” or “research-use-only” peptides advertised online claiming to be these molecules. Steer clear. These products sit outside any pharmacy oversight, with no guarantees on purity, sterility, dosing accuracy, or even that the vial contains what the label says. The trial doses described here reflect what researchers used under close medical supervision, not a protocol anyone can safely copy at home.<\/p>\n

Effective Options Are Already Here<\/h3>\n

If you’re weighing your choices today, the encouraging news is that highly effective treatments already exist. Tirzepatide, the drug retatrutide is most often compared to, is available now and produces substantial weight loss<\/a> for many people, as does semaglutide. You don’t have to wait years for the next molecule to start making progress<\/a>.<\/p>\n

A licensed provider can help you sort out which currently available medication fits your health history and your goals. If you want to find out whether treatment makes sense for you, TrimRx’s online intake quiz<\/a> is a straightforward place to begin.<\/p>\n

This article is for general educational purposes only and does not constitute medical advice. Amycretin and retatrutide are investigational drugs that have not been approved by the FDA for any use. They are not available by prescription or through TrimRx, and any product marketed as one of these compounds outside of a clinical trial is unregulated and potentially unsafe. Weight loss figures reflect findings from clinical trials and are not guarantees of individual results. Always talk with a qualified healthcare provider before starting, stopping, or changing any treatment, and never attempt to self-source or self-administer an investigational medication.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Amycretin and retatrutide are two of the most closely watched experimental obesity drugs in development, and they come from the two companies that already…<\/p>\n","protected":false},"author":7,"featured_media":106109,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-117789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/117789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=117789"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/117789\/revisions"}],"predecessor-version":[{"id":117790,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/117789\/revisions\/117790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/106109"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=117789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=117789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=117789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}